drugset / Trial / NCT02259725
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Phase 2
Completed
3 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2016-08-16
- Primary completion
- 2020-08-20
- Completion
- 2020-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | — | Oral |